CELA2A Antibody

What is CELA2A and why is it significant for metabolic research?

CELA2A (Chymotrypsin-Like Elastase Family, Member 2A) is a pancreatic elastase that has emerged as a significant protein in metabolic regulation, particularly in relation to insulin homeostasis and cardiovascular health. Research has revealed that CELA2A functions as a circulating enzyme that reduces platelet hyperactivation, triggers both insulin secretion and degradation, and increases insulin sensitivity . CELA2A was initially characterized as an "exocrine" pancreatic elastase that preferentially cleaves A-acetyl-L-alanyl-L-alanyl-L-alanine/proline methyl-ester and forms an SDS-resistant complex with alpha-1-antitrypsin (A1AT) . The significance of CELA2A in metabolic research has been highlighted by whole exome sequence analysis in kindreds with extreme phenotypes of early-onset atherosclerosis and metabolic syndrome, which identified novel loss-of-function mutations in the gene encoding CELA2A . These mutations compromise the elastase activity of the protein and are associated with metabolic syndrome traits, suggesting CELA2A's crucial role in metabolic health.

What is the tissue distribution of CELA2A and how does expression vary in disease states?

The tissue distribution of CELA2A provides important context for researchers designing experiments with CELA2A antibodies. While the highest mRNA and protein levels of CELA2A are found in the pancreas, significant expression has also been detected in the adrenal gland and small intestine in mouse models . In human tissue samples, immunohistochemistry has revealed intense staining in the exocrine pancreas, with a small fraction of cells in pancreatic islets also staining positive for CELA2A . Additional CELA2A expression has been observed in human adrenal cortex, intestinal glands, and colonic lymphoid follicles . Interestingly, disease states appear to alter CELA2A expression patterns, with data from Gene Expression Omnibus (GEO) showing elevated expression in tissues that otherwise have low or no expression, including skeletal muscle of insulin-resistant obese subjects and β cells of individuals with Type 2 Diabetes . Western blot analysis has confirmed CELA2A presence in human cadaveric pancreas, liver, and white adipose tissue, providing multiple potential targets for antibody-based research applications . This altered expression pattern in metabolic diseases reinforces the potential significance of CELA2A as a biomarker or therapeutic target.

How does CELA2A relate to insulin regulation and glucose metabolism?

CELA2A demonstrates a fascinating relationship with insulin regulation, making it particularly relevant for diabetes and metabolic syndrome research. Studies have shown that plasma CELA2A levels rise postprandially and parallel plasma insulin levels in healthy individuals, with virtually identical response patterns (R² coefficient 0.9) . This parallel surge of CELA2A and insulin suggests that CELA2A may function as an insulinotropic peptide . Direct experimental evidence supports this hypothesis, as treatment of size-matched primary rat islets with recombinant Cela2a (rCela2a) at 9 mM glucose concentration augmented insulin secretion compared to vehicle alone . Human islets treated with wild-type CELA2A similarly showed significantly higher C-peptide secretion and a tendency toward higher insulin secretion compared to controls . Mechanistically, proteomics and phosphoproteomics analyses of insulin-secreting cells (INS-1) treated with rCela2a revealed activation of protein kinase A (PKA) and higher levels of calcium channel phosphorylation, with subsequent dramatic increases in intracellular Ca²⁺ transients in the presence of glucose . These findings establish CELA2A as a significant player in glucose homeostasis and insulin secretion pathways, offering multiple experimental angles for researchers using CELA2A antibodies.

What applications are CELA2A antibodies validated for in research settings?

CELA2A antibodies have been validated for multiple research applications, providing versatile tools for investigating this protein's expression and function. Commercial antibodies, such as the rabbit polyclonal antibody raised against ELA2A (another name for CELA2A), have been specifically selected and validated for their ability to recognize CELA2A in immunohistochemical staining and western blotting . These antibodies can be utilized in Western Blotting (WB) to detect CELA2A protein expression levels and molecular weight variants, including the characteristic 25-kDa band and the 75-kDa SDS-resistant complex observed in human serum . Immunohistochemistry (IHC) applications allow researchers to visualize tissue distribution patterns of CELA2A, as demonstrated in studies identifying its expression in pancreas, adrenal gland, and intestinal tissues . Additionally, CELA2A antibodies have been validated for Immunoprecipitation (IP), enabling the isolation and characterization of CELA2A protein complexes, and for Immunocytochemistry (ICC), facilitating subcellular localization studies . The specificity of these antibodies has been rigorously verified through techniques such as pre-blocking with recombinant CELA2A and testing on CELA2A-transfected cell lines, ensuring reliable results in research applications .

What are the optimal protocols for Western blot detection of CELA2A in different tissue samples?

Optimizing Western blot protocols for CELA2A detection requires careful consideration of the protein's characteristics and tissue-specific expression patterns. When working with CELA2A, researchers should be aware that the protein appears in human plasma as both 25-kDa and 75-kDa bands, with the latter representing an SDS-resistant complex that persists despite denaturing conditions . For consistent and specific detection, polyclonal antibodies targeting amino acids 17-271 or other epitopes of CELA2A have been successfully employed . Sample preparation is particularly critical for CELA2A detection: pancreatic tissues, which express CELA2A at the highest levels, should be homogenized in protease inhibitor-containing buffer to prevent degradation by abundant proteases . For detecting circulating CELA2A in plasma or serum samples, it's advisable to first verify the absence of signal when the antibody is pre-blocked with recombinant CELA2A, as this control confirms specificity . When analyzing potential CELA2A mutations or variants, researchers should compare band patterns between wild-type and mutant proteins, noting that mutations such as p.D121N and p.T70M have been shown to affect the formation of the 75-kDa complex with A1AT . For tissues with lower expression levels, enrichment techniques or more sensitive detection systems may be necessary to visualize CELA2A bands clearly and confidently.

How can researchers optimize immunohistochemistry protocols for CELA2A detection in pancreatic and non-pancreatic tissues?

Optimizing immunohistochemistry protocols for CELA2A detection requires tissue-specific approaches due to varying expression levels and potential background issues. For pancreatic tissue, where CELA2A is most highly expressed, standard paraformaldehyde fixation followed by paraffin embedding works effectively, but antigen retrieval steps should be optimized as the catalytic domain might be masked . The antibody specificity for IHC applications should be validated by pre-blocking with recombinant CELA2A and testing on tissues known to have different expression levels, such as comparing pancreatic tissue (high expression) with skeletal muscle (low/no expression under normal conditions) . For non-pancreatic tissues with lower expression levels, such as adrenal gland and small intestine, signal amplification methods may be necessary, and longer primary antibody incubation times (overnight at 4°C) can improve detection sensitivity . When examining tissues with potential pathological changes in CELA2A expression, such as skeletal muscle in insulin-resistant subjects or β cells in Type 2 Diabetes patients, paired normal tissues should be included as controls to accurately assess expression differences . Additionally, dual immunofluorescence staining with cell-type-specific markers can help identify exactly which cells express CELA2A in heterogeneous tissues like pancreatic islets, where only a small fraction of cells stain positive for CELA2A amid predominantly insulin-producing β cells .

How can CELA2A antibodies be used to investigate mutations associated with metabolic syndrome and atherosclerosis?

CELA2A antibodies serve as crucial tools for investigating the functional consequences of CELA2A mutations linked to metabolic syndrome and atherosclerosis. Researchers can employ a multi-faceted antibody-based approach to characterize these mutations, beginning with Western blot analysis to assess protein expression and secretion patterns of wild-type versus mutant CELA2A in transfected cell models . This approach has already revealed that certain mutations (p.D121N, p.T70M) result in failure to form the characteristic 75-kDa complex with alpha-1-antitrypsin, providing insights into structural disruptions . Immunoprecipitation using CELA2A antibodies can isolate the protein complexes for mass spectrometry analysis, helping identify altered protein-protein interactions caused by mutations in the catalytic domain or other functional regions . For clinical samples from patients with identified CELA2A mutations, immunohistochemistry with antibodies can visualize altered tissue distribution patterns, while ELISA methods using these antibodies can quantify circulating levels of the protein in plasma, which have been found to differ between wild-type and mutant CELA2A carriers . When investigating dominant-negative effects of mutant proteins, co-expression studies followed by antibody-based detection can demonstrate how mutant CELA2A interferes with wild-type protein function, as evidenced by elastase activity assays showing that co-expressed wild-type and mutant CELA2A proteins exhibit significantly less activity than the sum of their individual activities .

What are the challenges in detecting circulating CELA2A in plasma/serum samples and how can they be overcome?

Detecting circulating CELA2A in plasma or serum samples presents several technical challenges that researchers must address for reliable results. The first major challenge is the presence of CELA2A in multiple forms – as a 25-kDa free protein and as part of a 75-kDa SDS-resistant complex with alpha-1-antitrypsin – requiring antibodies that can recognize both forms or specific epitopes that remain accessible in the complex . Background interference from abundant plasma proteins can mask CELA2A signals, necessitating optimization of blocking conditions and potentially pre-clearing samples of highly abundant proteins. Specificity verification is essential, as demonstrated in published research where western blot analysis of human serum with CELA2A antibody recognized both 75-kDa and 25-kDa bands that disappeared when the antibody was pre-blocked with recombinant CELA2A . Quantification methods must be carefully validated, particularly for ELISA approaches, by testing cross-reactivity between human and mouse CELA2A using purified wild-type and mutant proteins at different titers . Postprandial fluctuations in CELA2A levels add another layer of complexity, as plasma CELA2A levels rise after meals and parallel insulin levels, meaning that feeding status must be standardized when comparing samples . For functional studies of circulating CELA2A, researchers should consider measuring both protein levels (via ELISA) and elastase activity, as mutations can significantly reduce enzymatic function while protein remains detectable – plasma from mutation carriers showed greater than 1.75-fold reduction in elastase activity despite detectable CELA2A levels .

How can researchers differentiate between the effects of wild-type and mutant CELA2A in functional studies?

Differentiating between the effects of wild-type and mutant CELA2A in functional studies requires a sophisticated experimental design that incorporates multiple complementary approaches. Researchers should begin with purified recombinant proteins of both wild-type and mutant CELA2A variants, characterized for proper folding and stability, before conducting comparative functional assays . Elastase activity assays using synthetic substrates containing the canonical cleavage site can quantitatively demonstrate functional differences, as shown with the p.D121N mutation, which exhibited considerably lower elastase activity than wild-type CELA2A, and similarly with p.L85M, p.T70M, and splice variant CELA2A proteins . For investigating insulin regulation effects, researchers should employ isolated islet studies with wild-type and mutant CELA2A treatments, measuring insulin and C-peptide secretion under controlled glucose concentrations, as demonstrated in studies where human islets treated with wild-type CELA2A showed significantly higher C-peptide secretion compared to controls . Molecular mechanism investigations should include calcium imaging to assess differences in intracellular Ca²⁺ transients following CELA2A treatment, as rCela2a has been shown to dramatically increase calcium transients in insulin-secreting cells in the presence of glucose . Proteomics and phosphoproteomics approaches can comprehensively identify differential activation of signaling pathways, such as the observed activation of protein kinase A and phosphorylation of calcium channels following wild-type CELA2A treatment . Finally, co-expression studies with wild-type and mutant proteins can reveal dominant-negative effects, which have been observed when elastase activities of co-expressed proteins were significantly less than the sum of their individual activities .

How can CELA2A antibodies be utilized to investigate altered expression in diabetes and obesity models?

CELA2A antibodies offer powerful tools for investigating the altered expression patterns observed in diabetes and obesity models, providing insights into the protein's potential role in these metabolic disorders. Researchers should employ a systematic approach beginning with immunohistochemistry using validated CELA2A antibodies to map expression changes across tissues, particularly focusing on skeletal muscle of insulin-resistant obese subjects and β cells of Type 2 Diabetes patients, where Gene Expression Omnibus data has indicated elevated CELA2A expression despite normally low levels in these tissues . Quantitative western blot analysis using CELA2A antibodies can provide more precise measurement of protein level changes, complementing transcriptomic data and potentially revealing post-transcriptional regulation differences in disease states . For circulating CELA2A assessment, enzyme-linked immunosorbent assays (ELISA) using these antibodies can measure plasma levels in diabetic versus non-diabetic subjects, similar to studies that found higher plasma CELA2A levels in p.D121N-CELA2A mutation carriers compared to wild-type carriers . Functional correlations should be established by measuring both CELA2A protein levels and total plasma elastase activity, as documented in mutation carriers who showed elevated CELA2A levels but reduced elastase activity, suggesting potential compensatory mechanisms or altered protein function in disease states . For mechanistic studies in cell models, immunofluorescence with CELA2A antibodies can locate the protein subcellularly, potentially revealing altered trafficking or localization in metabolically stressed cells, while co-immunoprecipitation can identify disease-specific protein interaction partners .

What role could CELA2A play in platelet function and cardiovascular disease risk assessment?

CELA2A's unexpected role in reducing platelet hyperactivation positions it as a potential biomarker and therapeutic target for cardiovascular disease risk assessment. Researchers investigating this connection should begin with platelet aggregation assays comparing responses in the presence of wild-type versus mutant CELA2A, as loss-of-function mutations in CELA2A have been identified in kindreds with extreme phenotypes of early-onset atherosclerosis . Immunofluorescence and flow cytometry using CELA2A antibodies can detect potential CELA2A binding to platelet surfaces, helping elucidate the mechanism of interaction between this circulating enzyme and platelets . For clinical applications, researchers may develop ELISA-based assays using CELA2A antibodies to quantify plasma CELA2A levels in patients with various cardiovascular risk profiles, potentially establishing it as a novel biomarker complementary to traditional risk factors . The relationship between CELA2A, platelet function, and insulin sensitivity presents an intriguing connection to explore in metabolic syndrome, where platelet hyperreactivity often coincides with insulin resistance; researchers could use CELA2A antibodies to investigate this interrelationship in both clinical samples and experimental models . Mechanistic studies should examine how CELA2A modifications affect platelet signaling pathways, potentially through proteomics and phosphoproteomics approaches similar to those that revealed CELA2A's effects on calcium channels and protein kinase A in pancreatic beta cells . Finally, therapeutic potential could be assessed by developing and testing CELA2A mimetics or recombinant protein therapies that restore normal platelet function, using CELA2A antibodies to track biodistribution and target engagement .

How might CELA2A research contribute to understanding the connection between insulin resistance and cardiovascular complications?

CELA2A research offers a unique opportunity to explore the mechanistic links between insulin resistance and cardiovascular complications, potentially revealing new therapeutic targets at this critical interface. Researchers utilizing CELA2A antibodies could develop immunohistochemical and immunofluorescence protocols to map CELA2A expression changes across vascular tissues, pancreatic islets, and metabolic organs in animal models of insulin resistance, detecting shifts in expression patterns that might contribute to disease progression . Dual-staining approaches combining CELA2A antibodies with markers of vascular inflammation or insulin signaling components could reveal spatial relationships between CELA2A expression and pathological tissue changes . Functional studies examining how wild-type versus mutant CELA2A affects both insulin secretion and platelet activation in parallel experimental systems could elucidate the protein's dual role in metabolic and vascular homeostasis, as suggested by the identification of CELA2A mutations in kindreds with early-onset atherosclerosis and metabolic syndrome . Translational research could employ ELISA methods with CELA2A antibodies to measure circulating levels in patients with various combinations of insulin resistance and cardiovascular disease, potentially identifying subgroups where CELA2A dysregulation is particularly relevant . The postprandial dynamics of CELA2A, which parallel insulin secretion patterns in healthy individuals, could be investigated in insulin-resistant states to determine whether this synchronization becomes disrupted, contributing to both metabolic dysfunction and cardiovascular risk . Finally, systems biology approaches incorporating CELA2A antibody-based proteomics could map the protein's interactions with both insulin signaling networks and platelet activation pathways, potentially revealing common regulatory nodes that explain the clinical clustering of metabolic syndrome traits with cardiovascular complications .

What controls are essential when using CELA2A antibodies in various experimental applications?

Implementing rigorous controls is essential for generating reliable data with CELA2A antibodies across experimental applications. For western blotting, researchers should include both positive controls (recombinant CELA2A protein or lysates from tissues with high expression like pancreas) and negative controls (tissues known to lack CELA2A expression under normal conditions) . Antibody specificity should be verified through pre-absorption controls, where the antibody is pre-incubated with purified recombinant CELA2A before application, as demonstrated in studies where this approach eliminated the 75-kDa and 25-kDa bands detected in human serum . For immunohistochemistry applications, researchers should include isotype controls matching the CELA2A antibody's host species and immunoglobulin class, and validate staining patterns by comparing tissues with known differential expression levels, such as the strong signals observed in exocrine pancreas versus the more limited staining in pancreatic islets . When investigating CELA2A mutations, wild-type CELA2A constructs expressed in appropriate cell systems provide essential positive controls for comparing expression, secretion, and activity of mutant variants . For functional studies examining CELA2A's effects on insulin secretion or platelet activation, vehicle controls must be carefully matched to the CELA2A preparation, and dose-response relationships should be established to confirm specificity of observed effects . Cross-validation with multiple antibodies targeting different CELA2A epitopes can provide additional confidence in experimental results, particularly when exploring novel expression patterns in disease states where CELA2A is upregulated in tissues that normally show low expression .

How can researchers troubleshoot common problems with CELA2A detection in different experimental systems?

Troubleshooting CELA2A detection requires systematic approaches tailored to specific experimental challenges across different applications. When western blotting yields weak or absent signals, researchers should first verify antibody functionality using recombinant CELA2A as a positive control, then optimize protein extraction protocols specifically for CELA2A, which forms both 25-kDa monomers and 75-kDa complexes that are resistant to standard denaturing conditions . For detection difficulties in tissues with normally low expression, signal amplification systems or increased antibody incubation times may be necessary, while maintaining specificity through appropriate controls . Inconsistent immunohistochemistry results often stem from variability in tissue fixation and antigen retrieval; researchers should standardize these conditions and consider that CELA2A's catalytic domain, particularly the critical D121 residue, must remain accessible for some antibodies to bind effectively . When investigating CELA2A mutations using antibody-based methods, epitope availability may be affected by structural changes; selecting antibodies targeting conserved regions outside the mutation site is advisable . For functional studies where recombinant CELA2A shows unexpectedly weak effects, protein quality should be verified by measuring elastase activity on synthetic substrates containing the canonical cleavage site, as laboratory-purified wild-type CELA2A has shown weaker effects than commercial recombinant preparations in some experimental systems . False positive signals in plasma or serum assays can result from cross-reactivity with related proteases; these can be identified through mass spectrometry analysis of immunoprecipitated bands and controlled for in subsequent experiments . When comparing human and animal models, species-specific optimization is essential, as antibody performance may vary despite sequence homology, requiring validation with species-appropriate positive controls .

What considerations are important when designing experiments to study CELA2A's role in insulin regulation?

Designing robust experiments to study CELA2A's role in insulin regulation requires careful consideration of multiple physiological and methodological factors. Researchers should account for the dynamic, postprandial nature of CELA2A secretion, as plasma CELA2A levels rise after meals and closely parallel insulin levels (R² coefficient 0.9), suggesting experimental designs should standardize feeding status and include appropriate time-course measurements . When working with isolated islets or beta cell lines, glucose concentration is critical, as CELA2A's effects on insulin secretion are glucose-dependent; protocols should include both low (2.5 mM) and stimulatory (9 mM) glucose concentrations, with KCl stimulation as a viability control, following established paradigms . Dose-response relationships should be carefully established, as different CELA2A preparations may show varying potencies; for instance, wild-type CELA2A purified in laboratory conditions showed weaker effects on human islets than recombinant mouse Cela2a . Both insulin and C-peptide measurements should be included to distinguish between effects on insulin secretion versus degradation, as CELA2A has been shown to trigger both processes . Mechanistic studies should consider CELA2A's effects on calcium signaling, as proteomics analysis has revealed that recombinant Cela2a treatment increases phosphorylation of voltage-gated calcium channels and dramatically enhances intracellular Ca²⁺ transients in beta cells . For in vivo studies, researchers must consider potential confounding by the dual roles of CELA2A in insulin regulation and platelet function, designing experiments that can parse these effects through appropriate controls and parallel measurements of both metabolic and cardiovascular parameters .

How might single-cell analysis techniques enhance our understanding of CELA2A expression in heterogeneous tissues?

Single-cell analysis techniques offer transformative potential for elucidating CELA2A's complex expression patterns in heterogeneous tissues like pancreatic islets, where conventional methods have identified only "a small fraction of cells" staining positive for CELA2A amid predominantly insulin-producing β cells . By combining CELA2A antibody-based immunofluorescence with single-cell RNA sequencing (scRNA-seq), researchers could precisely identify which islet cell types express CELA2A, potentially revealing previously unrecognized expression in specific endocrine cell subpopulations or revealing rare CELA2A-expressing cells that are masked in bulk tissue analyses . Single-cell mass cytometry (CyTOF) using metal-conjugated CELA2A antibodies could provide quantitative protein expression data across thousands of individual cells, enabling correlation of CELA2A expression with established cell type markers and functional proteins in the insulin secretion pathway . This approach could be particularly valuable for investigating the elevated CELA2A expression observed in β cells of subjects with Type 2 Diabetes, potentially revealing whether this represents uniform upregulation across all β cells or induction in specific cellular subsets . Spatial transcriptomics combined with CELA2A immunostaining could preserve tissue architecture information while providing transcriptional profiles, elucidating whether CELA2A-expressing cells in the pancreas have particular anatomical distributions relative to blood vessels or other structural features . For mechanistic studies, single-cell calcium imaging following CELA2A treatment could reveal cell-to-cell variability in responses to this protein, potentially identifying cellular subpopulations particularly sensitive to CELA2A's effects on calcium channels and insulin secretion . These advanced single-cell approaches would substantially refine our understanding of CELA2A's tissue-specific roles and potentially identify new cellular targets for therapeutic intervention.

What proteomics approaches can reveal CELA2A's protein interaction network in metabolic regulation?

Advanced proteomics approaches offer powerful tools for mapping CELA2A's protein interaction networks and revealing its multifaceted roles in metabolic regulation. Proximity-labeling techniques such as BioID or APEX, combined with CELA2A antibodies for validation, could identify transient or weak interaction partners in living cells, providing dynamic information about CELA2A's functional environment in different metabolic states . Quantitative interaction proteomics using immunoprecipitation with CELA2A antibodies followed by mass spectrometry could compare wild-type versus mutant CELA2A interactomes, potentially explaining how mutations like p.D121N, which affects the catalytic domain, lead to metabolic dysfunction . Cross-linking mass spectrometry could map the structural details of CELA2A's interaction with alpha-1-antitrypsin, providing insights into the formation of the characteristic 75-kDa SDS-resistant complex that is absent in certain CELA2A mutations . Phosphoproteomics approaches have already revealed CELA2A's impact on signaling networks, showing activation of protein kinase A and phosphorylation of calcium channels in insulin-secreting cells treated with recombinant Cela2a, but could be extended to investigate additional posttranslational modifications and signaling pathways in various metabolic tissues . Temporal proteomics capturing changes in protein abundance and modifications at multiple timepoints after CELA2A treatment could elucidate the sequence of molecular events leading from CELA2A action to insulin secretion and other metabolic effects . For in vivo relevance, plasma proteomics comparing wild-type individuals with CELA2A mutation carriers could identify downstream biomarkers of altered CELA2A function, potentially revealing novel components of CELA2A-dependent pathways that contribute to metabolic syndrome and cardiovascular risk .

How could CRISPR-based approaches advance functional studies of CELA2A in metabolic disease models?

CRISPR-based approaches offer unprecedented precision for interrogating CELA2A function in metabolic disease models, enabling sophisticated experiments that previous technologies could not support. CRISPR-mediated knock-in of specific human CELA2A mutations identified in patients with early-onset atherosclerosis and metabolic syndrome, such as p.D121N, p.T70M, or p.L85M, could generate physiologically relevant animal models that recapitulate the human disease phenotype, allowing detailed study of disease progression and potential therapeutic interventions . Base editing or prime editing technologies could introduce precise point mutations in the catalytic domain, particularly targeting the evolutionarily conserved D121 residue, creating graduated series of mutations with varying impacts on elastase activity for structure-function analyses . Tissue-specific or inducible CELA2A knockout models using Cre-lox systems combined with CRISPR could dissect the relative contributions of CELA2A from different sources (pancreatic, circulating, or locally expressed in other tissues) to insulin regulation and cardiovascular function . For cellular studies, CRISPR activation (CRISPRa) or interference (CRISPRi) systems could modulate CELA2A expression in beta cells or other metabolic tissues without permanently altering the genome, allowing reversible manipulation of expression levels to study dose-dependent effects . Multiplexed CRISPR screening could identify genes that modify CELA2A-dependent phenotypes, potentially revealing new components of the pathways through which CELA2A influences insulin secretion and platelet activation . CRISPR-engineered reporter cell lines expressing fluorescent proteins under the control of the CELA2A promoter could enable live imaging of CELA2A expression dynamics in response to metabolic stimuli, providing insights into its regulation . CELA2A antibodies would remain essential in these CRISPR-based approaches for phenotypic validation, protein localization studies, and quantification of expression levels across experimental conditions .